![Medical News Asia | Powered by ['mediPr]](https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png)
Microorganisms are omnipresent, yet most of us do not get infected easily. Patients who are infected with the human immunodeficiency virus (HIV), however, are an exception. This can be attributed to host immunosuppression caused by the virus.
Coronavirus Disease 2019 (COVID-19) emerged in late 2019 and later transformed into a pandemic. Since the United States Food and Drug Administration (FDA) granted Emergency Use Authorisation for COVID-19 vaccines.
Delayed therapy start and antiretroviral therapy (ART) resistance are two common issues affecting up to 33% and 17% of patients infected with human immunodeficiency virus (HIV), respectively. These patients commonly present with higher viral loads, lower CD4 T-cell count, and complications such as infections requiring acute treatment. For those patients presenting with acquired immunodeficiency syndrome (AIDS) or those who have breakthrough HIV, and who present with opportunistic infections and comorbidities requiring hospitalisation, ART treatments are limited.
Human immunodeficiency virus (HIV), one of most serious public health challenges in the world, has already affected approximately 37.6 million people across the globe in 2020 and new infections in 2020 are estimated to be 1.5 million. Bictegravir/ Emtricitabine/ tenofovir (BIC/TAF/FTC) is a fixed-dose combination tablet consisting of an integrase inhibitor and two nucleoside reverse transcriptase inhibitors for the treatment of HIV infection. This HIV medication was approved by the United States Food and Drug Administration (USFDA) in 2018 due to the excellent efficacy outcomes in clinical trials. Real-world safety data of BIC/TAF/FTC was presented at the 18th European AIDS Conference in 2021 and summarised below.
As reported in The Lancet Child and Adolescent Health 2021, a cross-sectional study from the IMVASK cohort enrolled and investigated human immunodeficiency virus (HIV)-infected children who were previously treated with antiretroviral therapy (ART) for at least 2 years, and were compared against children of the same age without HIV.
There is no excerpt because this is a protected post.
Human immunodeficiency virus (HIV) has been transformed into a chronic disease to the successful introduction of antiretroviral therapy (ART), and people living with HIV (PWH) now experience morbidity from other chronic conditions, such as kidney, liver, and heart disease.
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
The incidence of anal cancer has been increasing over the past decade, but currently still constitutes 0.5% of all cancer diagnoses in the United States. When the cancer has metastasised, prognosis remains poor, with relative 5-year survival rates of approximately 30%. The current standard of care for metastatic anal cancer is cisplatin-based chemotherapy combined with 5-fluorouracil (5-FU). However, no randomised clinical trial investigating the optimal chemotherapy regimen for this disease has been conducted. The InterAAct trial was launched to investigate cisplatin plus FU against carboplatin plus paclitaxel in advanced anal cancers, and full results were recently published in the Journal of Clinical Oncology.